SFDA Approves Neusoft Mammography CAD
This article was originally published in PharmAsia News
Executive Summary
Chinese software provider Neusoft Medical System received China's State FDA certification for its proprietary mammary Computer-Aided Diagnosis (CAD) product. Industry observers note this shows local companies have the capacity to develop, manufacture and sell international-standard CAD devices designed for Asians. At present, only a few American and European countries can manufacture such sophisticated equipment. Moreover, the development of mammoCAD is based mainly on Western pathology databases, which differ from Asian characteristics and thus affect the latter's detection rate. To address this issue, Neusoft has worked with major breast cancer hospitals in Tianjin and Liaoning province to specifically tailor its product for the Asian market. (Click here for more - Chinese Language)
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.